News

A new study confirms this form of surveillance to collect metrics for SARS-CoV-2 to understand infection prevalence on a bigger scale.

The study was designed to help scientists better understand how to prevent in-hospital transmission of C difficile.

The federal agency’s Advisory Committee on Immunization Practices (ACIP) also added the recently approved therapeutic to the Vaccines for Children program.

A new study demonstrated Moderna having a greater efficacy and slightly less adverse event profile in this patient population vs the Pfizer-BioNTech vaccine.

Nonsteroidal anti-inflammatory drugs can work with Clostridioides difficile toxins to target mitochondria of epithelial cells, leading to increased severity of infection that can be long-lasting.

Marrazzo is currently the director of the Division of Infectious Diseases at the University of Alabama at Birmingham, and will assume her role at the NIAID in the fall.

For people living with chronic hepatitis D, the latest study results confirm the benefit of injections of this first-in-class entry inhibitor.

The vaccine targets an additional 8 unique serotypes that disproportionally affect the adult population.

The CDC made this recommendation after reviewing relevant literature, and noting that complete testing jumped from about only two-thirds of patients to nearly all patients.

The first FDA-approved fecal microbiota product maintained a positive safety profile in the largest safety evaluation to date with up to 2 years of safety data.

This day reflects the importance of remembering people who have been affected by the disease as well as a reminder to remain safe and get tested.

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.

The twice-yearly injectable shown to be beneficial in conjunction with an optimized background regimen.

A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.

A new study shows the use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events. The data is being reported at the International AIDS Society Conference.

New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.

Coverage this week included how COVID-19 vaccines in patients with cancer fared; analysis of non-COVID-19 adult vaccines; a company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b; and how a hospital modified testing for C difficile.

The federal agency gave the nod to Verrica Pharmaceuticals for its therapy, VP-102 (Ycanthe), for molluscum contagiosum (molluscum), making it the first treatment indicated for the viral-borne skin disease.

New report published this week shows the decrease over the last 2 reportable years.

The study is believed to be the first to examine such a broad array of patient groups.

This conference is addressing antimicrobial resistance (AMR) from different perspectives and look at strategies to reduce this global health problem.

Even if a patient has been vaccinated or previously infected, clinicians should still consider mpox if a patient presents with rash, the paper suggested.

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?

This study explores the effectiveness of PCR and toxin EIA testing in predicting C difficile infection (CDI) outcomes. The research reveals that patients with negative toxin results were less likely to experience CDI recurrence within 30 days.

The Gates Medical Research Institute (MRI) is conducting a study looking at the effect of bifidobacterium longum subspecies infantis (B infantis) as a supplement.

Rebyota, the first FDA-approved microbiota-based live biotherapeutic for preventing recurrent Clostridioides difficile infection (rCDI), has been the subject of a groundbreaking safety analysis.

Patients with cancer, cancer survivors, and matched controls maintained immunity against severe COVID-19 for at least 5 months after a third or fourth vaccine dose.